About Us

French Deeptech in the field of innovative antivirals

Signia Therapeutics

Signia Therapeutics is an innovative French start-up co-founded in April 2017 by a team of four French & Canadian scientists.

SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several market-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications. Signia Therapeutics's most advanced product is under a Phase II multicentric clinical evaluation (FLUNEXT trial) for the evaluation of one very promising antiviral candidate, with final results expected in 2019-2020.

Signia Therapeutics was laureate of the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance. The company has also been awarded the Seal of Excellence by the EU H2020 Framework Programme for Research and Innovation in 2018.

This project has received funding from the European Union’s Horizon 2020 Research and Innovation SME Instrument (grant agreement No 826722 - SIGNIA - H2020-SMEInst-2018-2020-1) and the European Innovation Council (EIC) Accelerator grant (grant agreement No 954353 - SIGNIA -)

This project has received funding from i-Lab bpiFrance

Signia Therapeutics was awarded with the label "French Tech Seed" in March 2019 by Pouss@LYS consortium

Legal mentions

Signia Therapeutics, Société par Actions Simplifiée au capital de 16.800 euros

Siège social : L’Atrium – 43 boulevard du 11 novembre 1918 69100 Villeurbanne

SIRET: 82888964200017

APE 7219Z TVA FR24828889642


Tel: 33(0)478776890

Directeur de la publication: Andrés Pizzorno, Président

Hébergeur: 1&1 Internet SARL

Contact us

Do not hesitate to contact us!

L’Atrium – 43 boulevard du 11 novembre 1918 69100 Villeurbanne, France
(+33) 478771037
Leave a comment

Signia therapeutics.com - Copyright 2018. All right reserved.